top of page
CASE STUDY
Interim prototype targeted platinum resistant ovarian cancer
Building from Pebble’s anti-inflammatory hypothesis and MD Anderson preclinical results, our optimized prototype achieved ongoing CA-125 stabilization and maintained absolute lymphocyte values, continuing through first two cycles of immunosuppressant Elahere.
bottom of page